FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W231297816> ?p ?o ?g. }

• W231297816 endingPage "923" @default.
• W231297816 startingPage "911" @default.
• W231297816 abstract "Modern oral contraceptive pills are safe and show minimal metabolic effects that have little clinical significance to smoking and reproductive age (even up to menopause). Multiphasic and 30 to 35 micrograms EE fixed combination pills are preferable to higher dose EE pills. Triphasic pills with norgestrel or norethindrone, monophasic norethindrone pills, and combination pills with the newer progestins are all probably metabolically comparable. The levonorgestrel implant is convenient, reversible, and effective and eliminates estrogenic metabolic effects. Metabolic benefits of the pill may include less acne, better preservation of bone mass, and less blood loss. Women who smoke should be encouraged to stop. Women with risk factors for atherosclerosis such as smoking, lipid abnormalities, diabetes, or hypertension should avoid combination pills. Women with a history of pregnancy, steroid-related thrombophlebitis, or thromboembolic disease should not use estrogen-containing pills.In the past 30 years mortality from coronary artery disease has decreased in the United States. From 1968 to 1976 it went down from 16.3 deaths among women aged 35-40 to 11.1 deaths/100,000 populations. Among women aged 45-54 the rate decreased from 72.8 to 56.5/100,000. A 1979 study examined the effect of combined oral contraceptives (OCs) on blood lipids in 1500 women using levonorgestrel or LNG pills (150-250 mcg monophasic and 50-75-125 triphasic), norethindrone (.5-1 mg) pills with 30-40 mcg of ethinyl estradiol (EE), and progestin-only preparations. The combination OCs increased triglycerides by 13-75% while progestins did not increase them. Total cholesterol did not change: LDL and HDL II decreased slightly. Another study, the Triphasic Randomized Clinical Trial (TRACT) probe, included 150 women using triphasic OCs: 35 mcg of norethindrone; 30-40-30 mcg of EE, 50-75-125 mcg of norgestrel; or 24 mcg of E, 500-1000-500 mcg of norethindrone. LDL increased from 0 to 11% and HDL II decreased by 29-33% after 6 months of OC use. The rise in HDL and HDL II and fall of LDL was observed in a 1990 study of 150 mcg desogestrel and 30 mcg of EE (Marvelon). OCs with 250 mcg of LNG produced the greatest drop of HDL II. Higher dose OCs used before the 1990s increased glucose levels, plasma insulin levels (especially with norgestrel), and reduced glucose tolerance (particularly by 50 mcg of EE). OCs with 150 mcg of desogestrel and 30 mcg of EE slightly increased C-peptide levels, but insulin and glucose level increases were marked. Thromboembolitic changes via clotting factor alterations were similar after the use of OCs with 30-35 mcg EE, triphasics, or new progestins. LNG implants (Norplant) significantly reduced HDL cholesterol and slightly lowered HDL II, while somewhat increasing serum glucose and insulin." @default.
• W231297816 created "2016-06-24" @default.
• W231297816 creator A5019914550 @default.
• W231297816 date "1991-12-01" @default.
• W231297816 modified "2023-09-26" @default.
• W231297816 title "Update on the Metabolic Effects of Steroidal Contraceptives" @default.
• W231297816 cites W1688235973 @default.
• W231297816 cites W1846043504 @default.
• W231297816 cites W1966376345 @default.
• W231297816 cites W1966623095 @default.
• W231297816 cites W1967177798 @default.
• W231297816 cites W1982069935 @default.
• W231297816 cites W1994495403 @default.
• W231297816 cites W2002637063 @default.
• W231297816 cites W2007379413 @default.
• W231297816 cites W2007576665 @default.
• W231297816 cites W2026522460 @default.
• W231297816 cites W2042860615 @default.
• W231297816 cites W2044072825 @default.
• W231297816 cites W2053622868 @default.
• W231297816 cites W2072287449 @default.
• W231297816 cites W2080555015 @default.
• W231297816 cites W2084964825 @default.
• W231297816 cites W2087015989 @default.
• W231297816 cites W2116066447 @default.
• W231297816 cites W2132000788 @default.
• W231297816 cites W2337024630 @default.
• W231297816 cites W2399797509 @default.
• W231297816 cites W2596242802 @default.
• W231297816 cites W4255773516 @default.
• W231297816 doi "https://doi.org/10.1016/s0889-8529(18)30250-0" @default.
• W231297816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1778182" @default.
• W231297816 hasPublicationYear "1991" @default.
• W231297816 type Work @default.
• W231297816 sameAs 231297816 @default.
• W231297816 citedByCount "7" @default.
• W231297816 countsByYear W2312978162012 @default.
• W231297816 countsByYear W2312978162023 @default.
• W231297816 crossrefType "journal-article" @default.
• W231297816 hasAuthorship W231297816A5019914550 @default.
• W231297816 hasBestOaLocation W2312978161 @default.
• W231297816 hasConcept C126322002 @default.
• W231297816 hasConcept C131872663 @default.
• W231297816 hasConcept C134018914 @default.
• W231297816 hasConcept C2776493420 @default.
• W231297816 hasConcept C2776607906 @default.
• W231297816 hasConcept C2777148285 @default.
• W231297816 hasConcept C2777164284 @default.
• W231297816 hasConcept C2778462979 @default.
• W231297816 hasConcept C2778562196 @default.
• W231297816 hasConcept C2779076696 @default.
• W231297816 hasConcept C2779441745 @default.
• W231297816 hasConcept C2780186607 @default.
• W231297816 hasConcept C2781039349 @default.
• W231297816 hasConcept C2908647359 @default.
• W231297816 hasConcept C29456083 @default.
• W231297816 hasConcept C2986740045 @default.
• W231297816 hasConcept C2986817661 @default.
• W231297816 hasConcept C42407357 @default.
• W231297816 hasConcept C71924100 @default.
• W231297816 hasConcept C81603835 @default.
• W231297816 hasConcept C98274493 @default.
• W231297816 hasConcept C99454951 @default.
• W231297816 hasConceptScore W231297816C126322002 @default.
• W231297816 hasConceptScore W231297816C131872663 @default.
• W231297816 hasConceptScore W231297816C134018914 @default.
• W231297816 hasConceptScore W231297816C2776493420 @default.
• W231297816 hasConceptScore W231297816C2776607906 @default.
• W231297816 hasConceptScore W231297816C2777148285 @default.
• W231297816 hasConceptScore W231297816C2777164284 @default.
• W231297816 hasConceptScore W231297816C2778462979 @default.
• W231297816 hasConceptScore W231297816C2778562196 @default.
• W231297816 hasConceptScore W231297816C2779076696 @default.
• W231297816 hasConceptScore W231297816C2779441745 @default.
• W231297816 hasConceptScore W231297816C2780186607 @default.
• W231297816 hasConceptScore W231297816C2781039349 @default.
• W231297816 hasConceptScore W231297816C2908647359 @default.
• W231297816 hasConceptScore W231297816C29456083 @default.
• W231297816 hasConceptScore W231297816C2986740045 @default.
• W231297816 hasConceptScore W231297816C2986817661 @default.
• W231297816 hasConceptScore W231297816C42407357 @default.
• W231297816 hasConceptScore W231297816C71924100 @default.
• W231297816 hasConceptScore W231297816C81603835 @default.
• W231297816 hasConceptScore W231297816C98274493 @default.
• W231297816 hasConceptScore W231297816C99454951 @default.
• W231297816 hasIssue "4" @default.
• W231297816 hasLocation W2312978161 @default.
• W231297816 hasLocation W2312978162 @default.
• W231297816 hasOpenAccess W231297816 @default.
• W231297816 hasPrimaryLocation W2312978161 @default.
• W231297816 hasRelatedWork W1972652118 @default.
• W231297816 hasRelatedWork W1995083997 @default.
• W231297816 hasRelatedWork W2019093682 @default.
• W231297816 hasRelatedWork W2041926443 @default.
• W231297816 hasRelatedWork W2148601805 @default.
• W231297816 hasRelatedWork W4234355880 @default.
• W231297816 hasRelatedWork W4298367744 @default.
• W231297816 hasRelatedWork W1625217825 @default.

• next